Fig. 2.

GSK2193874 inhibits TRPV4 expression in the hippocampus of rats exposed to soman. Protein expression of TRPV4 was assessed by (A) Western blotting and (B) immunofluorescence (red, TRPV4; blue, Hoechst; ×200, original magnification; scale bars, 50 μm). TRPV4⁺/Hoechst⁺ cells are TRPV4-positive cells, and Hoechst⁺ cells are total cells. Soman group: rats were treated with HI-6 (125 mg/kg i.p.) before soman injection (160 μg/kg, s.c.); GSK2193874 (GSK) group: rats were additionally treated with the TRPV4 antagonist GSK2193874 (1 mg/kg, i.v.) immediately after HI-6 injection and before soman injection; Control group: rats received HI-6 and solvent instead of antagonist and soman (mean ± SD, n = 6; ***P <0.001 vs control group, ^#P <0.05 vs soman group, one-way ANOVA and Dunnett’s multiple comparison test).